INTRODUCTION
Over the past few years, many nucleoside analogs have been synthesized in the search for new antiviral agents. Of the few that have been useful as antiviral agents, most have a limited range of in vitro effectiveness. However, ribavirin (1-3-D-ribofuranosyl-lH-1,2,4-triazole-3-carboxamide; Mr, 244, 200 ) is an antiviral agent that has shown in vitro activity against a broad spectrum of DNA and RNA viruses (8, 20, 34) . This antiviral activity is due to the resemblance of this compound to nucleosides. Ribavirin has shown clinical efficacy against both influenza A and B virus (12, 21, 27) , respiratory syncytial virus (RSV) (11, 15, 16, 29) , and parainfluenza virus infections (11, 29) and Lassa fever (28) . Ribavirin is in clinical trials to test its effectiveness against herpesvirus, human T-cell lymphotropic virus type III/lymphadenopathy-associated virus, and a variety of exotic viral diseases. In this report, we summarize the current data on ribavirin as to chemical structure, possible mode(s) of action, metabolic disposition, and clinical use as an antiviral agent.
STRUCTURAL AND BIOCHEMICAL CHARACTERISTICS OF RIBAVIRIN In 1972 , ribavirin was synthesized by chemically combining derivatives of 1,2,4-triazole-3-carboxamide and ribofuranoside (49) and shown to have promise as a broadspectrum antiviral agent (35) . Subsequent studies showed that ribavirin most closely resembles guanosine, as determined by X-ray crystallography ( Fig. 1) (31) . Although not all enzyme systems utilize ribavirin as they do guanosine, it has been shown that many of the systems that are inhibited by ribavirin are reversed by the addition of guanosine (38) . An important exception is adenosine kinase, which traps ribavirin within the cell (41, 46) but does not utilize guanosine as a substrate (30) .
The antiviral activity of ribavirin is quite specifically associated with its structure. Alterations to either the ribose moiety or to the base result in a substantial loss of antiviral activity (38) . However, additions to the hydroxyl groups (e.g., acetylation, phosphorylation) or conversion of the carboxamide group on the triazole to a carboxamidine retains antiviral activity, presumably due to the biological conversion of these compounds back to ribavirin. Ribavirin triacetate has been shown to be more effective than ribavirin in the treatment of dengue virus and Colorado tick fever virus encephalitis in experimental animals (23, 36) . It has been suggested that the hydrophobic nature of the triacetate form allows ribavirin to remain longer in tissues and to cross the blood-brain barrier. (51) showed that the anti-influenza virus activity of ribavirin increases progressively with reduction in GTP intracellular pools up to 25 F.M. As ribavirin concentrations were further increased, the antiviral effect progressively increased to 95% inhibition at 100 I.M, but without further reduction in GTP pools. In addition, the 1,4,5-triazole derivative of ribavirin has potent IMP dehydrogenase inhibitory activity but does not have antiviral activity (38) .
RTP inhibits the GTP-dependent capping of the 5' end of viral mRNAs. Enzymes isolated and purified from vaccinia virus and which are responsible for the addition of GTP to the 5' end of newly synthesized viral mRNA (i.e., capping reaction) are inhibited by RTP (13) . Because influenza virus requires the simultaneous synthesis of capped host mRNAs for the synthesis of its own mRNAs (24) , the inhibition of similar host cell capping enzymes may be an important mechanism. A similar role in other viral infections has not been established, but capped mRNAs are central to most viral replication schemes. Canonico reported that vesicular stomatitis virus mRNA isolated from ribavirin-treated BHK-21 cells infected with vesicular stomatitis virus is translated in an in vitro protein-synthesizing system with only 30% efficiency when compared with untreated control mRNAs (3). These studies suggested that ribavirin treatment of vesicular stomatitis virus-infected cells results in the production of altered mRNA species and that this alteration is in the 5'-cap formation of the viral mRNA.
RTP has been shown to inhibit directly the influenza virus RNA polymerase complex (9, 50) . The synthesis of each of the eight viral mRNAs by enzymes contained in the polymerase complex depends on a two-step mechanism (24).
Step 1 is the use of newly synthesized host 5'-capped mRNA to prime and initiate mRNA synthesis at the 3' end of viral genomes and is most probably mediated by the polymerase complex proteins, PB2 and PB1. The mRNA primer is generated by endonucleolytic cleavage of the capped mRNA at a purine residue 10 to 13 nucleotides from the cap. The endonuclease (PB2 activity) requires the presence of the 5'-terminal methylated cap structure. Initiation of transcription is mediated by the incorporation of a guanosine residue onto the 3' end of the capped primer fragment generated by the endonuclease (PB2 and PB1 activity).
Step 2 in the reaction is the elongation of the mRNA (complementary to the virion RNA) following the addition of the guanosine residue and is most probably mediated by the PB1 enzyme of the polymerase complex. Thus, guanosine molecules are involved in cap recognition and initiation and elongation reactions. Although RTP inhibits the latter two steps, it is more active in preventing the elongation of the viral mRNAs than in blocking initiation (50) . Thus, all three or any one of the foregoing mechanisms may be operational at any one time, depending on the virus infection. This potential for inhibition at more than one site may explain the failure to detect viral isolates resistant to ribavirin (15, 47 (48) , and parainfluenza (Sendai) virus (25) ; cotton rats infected with the Long strain of RSV (17) ; and monkeys infected with influenza A/Aichi/2/68 virus (40) and Lassa fever virus (18, 19) . Small-particle aerosol administration of ribavirin to mice infected with influenza A or B virus was shown to be more effective than intraperitoneal treatment (39, 45, 48 The use of ribavirin in a small-particle aerosol has been evaluated in double-blind, placebo-controlled studies of influenza infections in college students (lla) and in RSV infections of infants with and without complications (15, 44 In 1981, ribavirin aerosol was used in the treatment of RSV infections in infants. In randomized, double-blind, placebo-controlled studies, infants presenting with bronchiolitis with (15) and without (44) pneumonia were treated with ribavirin aerosol. All patients were infected with RSV at the start of treatment. Hall et al. (15) treated patients for an average of 20 h daily for 3 to 5 days at an estimated dosage of 0.82 mg/kg per h. Treated patients recovered more rapidly from illness, had earlier disappearance of RSV from respiratory secretions, and at the end of the treatment period had higher arterial oxygen saturations than control patients. In a more recent study, Hall et al. (14) treated infants with RSV infections and complicating cardiopulmonary disease. In this study, patients treated with ribavirin aerosol shed less virus, illness disappeared more rapidly, and arterial oxygen saturation increased more rapidly than in control patients. Infants requiring assisted ventilation also were treated and responded more rapidly to ribavirin treatment than did control patients.
An impressive demonstration of the virustatic effect of ribavirin and the importance of an intact immune system to the elimination of virus is seen in the treatment of RSV and parainfluenza virus infections in children with severe combined immune deficiency disease. In 1983, Gelfand et al. (11) treated a 5-month-old child who had respiratory disease caused by parainfluenza virus type 3 and who also was immune deficient. Ribavirin aerosol treatment was followed by the disappearance of the virus from respiratory secretions, a decrease in fever, and an increase in arterial oxygen saturation. After cessation of treatment at 5 days, the disease reappeared, but it disappeared with further treatment. After six courses of treatment, while the disease was in remission, a successful bone marrow transplantation was performed. McIntosh et al. (29) reported similar results in an infant with severe combined immune deficiency and RSV infection. These studies demonstrated that ribavirin can inhibit virus replication in the respiratory tract but that an intact immune system is important for sustained recovery.
PHARMACOKINETICS AND TOXICITY OF RIBAVIRIN
The metabolism and tissue distribution of ribavirin have been studied extensively in rats, but unfortunately this is of limited value because ribavirin is metabolized differently in nonhuman primates and humans (6, 10) . Ribavirin is excreted more slowly and is retained in all tissues, except the brain, to a greater extent in monkeys than in rats. Thus, extrapolations should be made with caution. Distribution studies in monkeys have shown that when given orally or intravenously, less than 1% of total body ribavirin is found in the lungs 8 h after the injection of 10 mg of ['4C]ribavirin per kg of body weight and that 45 to 60% is excreted in the urine within 72 h (6, 10). In contrast, small-particle aerosol administration deposits 70% of the inhaled drug directly onto the respiratory epithelium (V. Knight, B. E. Gilbert, and S. Z. Wilson, Proc. Int. Symp. Med. Virol., in press). After oral administration, the excretion pattern of ribavirin in humans has a similar metabolic fate, with the major excretory products being undegraded and deribosylated ribavirin. The estimated half-life of ribavirin in respiratory excretions and plasma after aerosol administration is approximately 2 and 9 h, respectively (5) . After oral administration, the estimated half-life of ribavirin in urine and erythrocytes is approximately 10 to 12 h and 40 days, respectively (6) . The long half-life in erythrocytes is due to the concentration of RTP in these cells, because they presumably lack the enzymes necessary for the efficient dephosphorylation of RTP. Information is not available concerning the half-life of ribavirin in erythrocytes after aerosol treatment.
Ribavirin administered parenterally has been shown to cause a dose-dependent transient anemia in monkeys resulting from more rapid extravascular clearing of erythrocytes and, at higher doses, the suppression of the release of late erythroid elements from the bone marrow (4, 33) . Early studies on the oral administration of ribavirin to treat influenza virus-infected patients reported elevated bilirubin values (7, 26, 37) . These elevated values may reflect more rapid extravascular clearance and destruction of the ribavirincontaining erythrocytes. In patients with Lassa fever treated orally or intravenously with higher doses of ribavirin, a transient anemia also was observed (28) . Such side effects, however, have not been detected in patients treated with ribavirin administered by small-particle aerosol, possibly because the pulmonary route of administration leads to slow diffusion into the cirulatory system and the dosage is low and of short duration. Treatment of premature or newborn infants or infants with underlying disease (i.e., bronchopulmonary dysplasia, congenital heart disease, severe combined immune deficiency) by small-particle aerosol also has been performed without detectable side effects.
CONCLUSIONS
Ribavirin is a purine nucleoside analog exhibiting in vitro antiviral activity against a wide variety of common and exotic viruses. It is metabolized intracellularly to its 5'-phosphate derivatives, which directly or indirectly inhibit viral replication, and in humans is rapidly excreted in the urine unchanged or as the deribosylated product. Animal model studies have clearly shown the effectiveness of ribavirin aerosol in the treatment of influenza A and B virus, RSV, and parainfluenza virus infections. Ribavirin administered to humans as a small-particle aerosol is rapidly deposited throughout the respiratory tract and attains concentrations that are inhibitory to both influenza A and B viruses and RSV. In clinical trials, ribavirin aerosol has been effective in the treatment of influenza A and B virus and RSV, whereas oral ribavirin appears to be effective in the treatment of acute hepatitis A virus infections, measles, and Lassa fever. Although transient anemias and elevated bilirubin levels have been reported for the oral or intravenous administration of ribavirin, these side effects have not been observed with small-particle aerosol treatment. We believe that the administration of ribavirin (and possibly VOL. 30, 1986 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from other antiviral agents) by small-particle aerosol for the treatment of viral respiratory infections opens new avenues for increasing the effectiveness while decreasing the toxicity of current and future antiviral therapy.
